Floatz logo

EF-5

Adult Oligodendroglioma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Oligodendroglioma cohort.

Asset / SponsorPhaseRating
Perifosine
National Cancer Institute (NCI)
Phase 1/2CCC
Plerixafor
Lawrence Recht
Phase 1/2CCC
Temsirolimus
National Cancer Institute (NCI)
Phase 1/2CCC
Alisertib
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 1CC
Isotretinoin
Wake Forest University Health Sciences
Phase 1CC

View all 10 →

Same molecule, other indications

EF-5 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Stage I Ovarian Epithelial CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →